Latest & greatest articles for prostate cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prostate cancer

761. Economic impact of different preparations of leuprolide acetate in the management of advanced prostate cancer

:1199-203. Crawford DE, Sartor O, Chu F, et al. A 12 month clinical study of LA-2585(45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol 2006;175:533-6. Alloul K, Sauriol L, Lafortune L. Meta-analysis and economic evaluation of LH-RH agonists' depot formulations in advanced prostatic carcinoma. Can J Urol 1998;5:585-94. Indexing Status Subject indexing assigned by CRD MeSH Clinical Trials as Topic; Cost-Benefit Analysis; Germany (...) Economic impact of different preparations of leuprolide acetate in the management of advanced prostate cancer Economic impact of different preparations of leuprolide acetate in the management of advanced prostate cancer Economic impact of different preparations of leuprolide acetate in the management of advanced prostate cancer Odeyemi I A, Berges R, Bolodeoku J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract

2007 NHS Economic Evaluation Database.

762. Survival associated with treatment vs observation of localized prostate cancer in elderly men. Full Text available with Trip Pro

Survival associated with treatment vs observation of localized prostate cancer in elderly men. Prostate-specific antigen screening has led to an increase in the diagnosis and treatment of localized prostate cancer. However, the role of active treatment of low- and intermediate-risk disease in elderly men is controversial.To estimate the association between treatment (with radiation therapy or radical prostatectomy) compared with observation and overall survival in men with low- and intermediate (...) -risk prostate cancer.Observational US cohort from Surveillance, Epidemiology, and End Results Medicare data.At total of 44,630 men aged 65 to 80 years who were diagnosed between 1991 and 1999 with organ-confined, well- or moderately differentiated prostate cancer and who had survived more than a year past diagnosis. Patients were followed up until death or study end (December 31, 2002). Patients were classified as having received treatment (n=32,022) if they had claims for radical prostatectomy

2006 JAMA

763. Radical prostatectomy reduced death and progression more than watchful waiting in early prostate cancer Full Text available with Trip Pro

☆ Nephrology ★★★★★★☆ METHODS Design: randomised controlled trial (Scandinavian Prostate Cancer Group Study Number 4). Allocation: {concealed} . Blinding: blinded {outcome assessors, data safety and monitoring committee, and data analysts} . Follow-up period: mean 8.5–8.8 years (median 8.2 y). Setting: 14 centres in Sweden, Finland, and Iceland. Patients: 695 men <75 years of age (mean age 65 y) with newly diagnosed, untreated, localised prostate cancer; tumour stage T0d (later changed to T1b), T1, or T2 (...) conclusions in favour of RP. It would be difficult now to defend such a policy: WW has been replaced by active surveillance. This is not mere semantics; patients are followed closely and at any hint of disease progression, appropriate systemic therapy is started. The study did not include radiotherapy, either external beam (EBRT) or brachytherapy. Both forms are effective in early prostate cancer, but no modern randomised trials have compared radiotherapy with either WW or RP. The ProtecT study in the UK

2006 Evidence-Based Medicine

764. Chemotherapy for hormone-refractory prostate cancer. (Abstract)

Chemotherapy for hormone-refractory prostate cancer. Prostate cancer mainly affects elderly men, and its incidence has steadily increased over the last decade. The management of this disease is replete with controversy. In men with advanced, metastatic prostate cancer, hormone therapy is almost universally accepted as the initial treatment of choice and produces good responses in most patients. However, many patients will relapse and become resistant to further hormone manipulation; the outlook (...) for these patients is poor. Many have disease extending to the skeleton, which is associated with severe pain. Therapies for these men include chemotherapy, bisphosphonates, palliative radiotherapy, and radioisotopes. Systemic chemotherapy has been evaluated in men with hormone-refractory prostate cancer (HRPC) for many years, with disappointing results. However, more recent studies with newer agents have shown encouraging results. There is therefore a need to explore the value of chemotherapy

2006 Cochrane

765. Gleason score predicted mortality rate to 20 years for untreated early prostate cancer Full Text available with Trip Pro

in Connecticut, USA. Patients: 767 men 55–74 years of age (mean age 69 y) diagnosed with clinically localised prostate cancer between 1 January 1971 and 31 December 1984 who were treated with observation or immediate or delayed androgen withdrawal therapy. Exclusion criteria were surgery, radiation therapy, brachytherapy, known metastatic disease, concomitant cancer, or survival <6 months. Prognostic factors: age at diagnosis, treatment method, comorbid conditions, and tumour grade according to Gleason score (...) (range 2–10; 10 = most undifferentiated). Outcomes: death from prostate cancer or other competing causes. MAIN RESULTS Prostate cancer mortality rates were 33 deaths per 1000 person years (95% CI 28 to 38) in the first 15 years of follow up and 18 deaths per 1000 persons years (CI 10 to 29) after 15 years. After adjusting for Gleason score, the rates before and after 15 years did not differ (rate ratio 1.1, CI 0.6 to 1.9). Men with low grade tumours had low risk of dying from prostate cancer over

2006 Evidence-Based Medicine

766. Viewpoint: limiting prostate cancer screening. (Abstract)

Viewpoint: limiting prostate cancer screening. Prostate cancer screening is controversial, and major professional associations offer differing screening guidelines. The author addresses 3 key issues about prostate cancer screening: 1) the prostate-specific antigen (PSA) criteria to recommend a prostate biopsy, 2) the appropriate age to start screening, and 3) the appropriate age to stop screening. The author argues, on the basis of evidence published since 2000, that data supporting

2006 Annals of Internal Medicine

767. Viewpoint: expanding prostate cancer screening. (Abstract)

Viewpoint: expanding prostate cancer screening. Prostate cancer screening is controversial, and major professional associations offer differing screening guidelines. The authors address 3 key issues about prostate cancer screening: 1) the prostate-specific antigen (PSA) criteria to recommend a prostate biopsy, 2) the appropriate age to start screening, and 3) the appropriate age to stop screening. The authors argue, on the basis of evidence published since 2000, that data supporting

2006 Annals of Internal Medicine

768. High dose rate brachytherapy in combination with external-beam radiotherapy for localised prostate cancer (IPG174)

in the development of this guideline which has led to this more specific recommendation. More information is available from . The IP guidance on high dose rate brachytherapy in combination with external-beam radiotherapy for localised prostate cancer remains current, and should be read in conjunction with the clinical guideline. Description Prostate cancer is one of the most common cancers in men. It tends to affect older men, with the risk rising with age. It is not a single disease entity but may be indicated (...) from an incidental biopsy finding to presentation with metastatic prostate cancer, which may or may not cause any symptoms or shorten life. Symptoms when they occur include urinary outflow obstruction and features of metastases, such as bone pain. Prognosis with prostate cancer is variable and depends on the grade of the tumour and stage of the diagnosed cancer. Treatment options depend on the stage of the cancer. Brachytherapy is a form of radiotherapy in which delivery of radiation is targeted

2006 National Institute for Health and Clinical Excellence - Interventional Procedures

769. Docetaxel for the treatment of hormone-refractory metastatic prostate cancer (TA101)

Docetaxel for the treatment of hormone-refractory metastatic prostate cancer (TA101) Overview | Docetaxel for the treatment of hormone-refractory metastatic prostate cancer | Guidance | NICE Docetaxel for the treatment of hormone-refractory metastatic prostate cancer Technology appraisal guidance [TA101] Published date: 28 June 2006 Share Guidance on docetaxel for treating hormone-refractory metastatic prostate cancer in adults. Guidance development process Is this guidance up to date? . We

2006 National Institute for Health and Clinical Excellence - Technology Appraisals

770. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. Full Text available with Trip Pro

Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. Despite a stage-shift to earlier cancer stages and lower tumor volumes for prostate cancer, pathologically advanced disease is detected at radical prostatectomy in 38% to 52% of patients. However, the optimal management of these patients after radical prostatectomy is unknown.To determine whether adjuvant radiotherapy improves metastasis-free survival in patients with stage pT3 N0 M0 prostate (...) undergone radical prostatectomy for pathologically advanced prostate cancer, adjuvant radiotherapy resulted in significantly reduced risk of PSA relapse and disease recurrence, although the improvements in metastasis-free survival and overall survival were not statistically significant. Trial Registration clinicaltrials.gov Identifier: NCT00394511.

2006 JAMA Controlled trial quality: predicted high

771. Program for the treatment of prostate cancer

outcomes in men with locally advanced prostate cancer. Hormonal therapy aims to reduce the size of the tumour, making subsequent radiotherapy more effective. Laverdiere et al (1997) found that either three or six months of androgen deprivation prior to radiotherapy improved local disease control two years after treatment relative to radiotherapy alone. Another study by Pilepich et al (2001) found that four months of androgen deprivation before and during radiotherapy improved outcomes on all measures (...) included local failure and prostate-cancer-specific survival. Local failure was defined as the time to tumour recurrence, or in cases where the primary tumour never disappeared, was defined as occurring at random. In measuring prostate-cancer- specific survival, death was attributed to prostate cancer if the patient had progressive prostate cancer, otherwise the observation was censored. Secondary outcomes included distant failure, biochemical failure, disease-free survival and freedom from salvage

2006 Australia and New Zealand Horizon Scanning Network

772. Dose verification system for the measurement of radiation dose in patients undergoing radiotherapy for breast and prostate cancer

HealthPACT through funding. This Horizon scanning prioritising summary was prepared by Tom Sullivan and Tracy Merlin from the National Horizon Scanning Unit, Adelaide Health Technology Assessment, Discipline of Public Health, Mail Drop 511, University of Adelaide, South Australia, 5005. PRIORITISING SUMMARY REGISTER ID: 000227 NAME OF TECHNOLOGY: DOSE VERIFICATION SYSTEM PURPOSE AND TARGET GROUP: MEASURING THE RADIATION DOSAGE RECEIVED AT THE TUMOUR SITE IN PATIENTS WITH BREAST OR PROSTATE CANCER STAGE (...) for improving the precision of radiotherapy in the treatment of breast or prostate cancer. BACKGROUND Radiotherapy has become a conventional treatment option for patients with early and late stage cancer. The effectiveness of proton beam radiotherapy has been associated with a number of patient-level factors; including age, comorbidities, and tumour features such as location, size and aggressiveness (Siegelmann-Danieli et al 2006). Successful radiotherapy also depends on accurate radiation delivery

2006 Australia and New Zealand Horizon Scanning Network

773. Performance of tPSA and f/tPSA for prostate cancer in Chinese: a systematic review and meta-analysis

Performance of tPSA and f/tPSA for prostate cancer in Chinese: a systematic review and meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 DARE.

774. Cryoablation for prostate cancer

cryoprobes to freeze and, thereby, destroy cancerous prostate tissue. Cryoablation is being investigated as a primary treatment alternative to surgery or radiotherapy for clinically localized prostatic carcinoma and as a second line or salvage treatment for patients with residual or recurrent cancer following radical prostatectomy or irradiation. Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH Cryosurgery /utilization; Prostatic Neoplasms (...) Cryoablation for prostate cancer Cryoablation for prostate cancer Cryoablation for prostate cancer Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Cryoablation for prostate cancer. Lansdale: HAYES, Inc.. Directory Publication. 2006 Authors' objectives Cryoablation for prostate cancer is a minimally invasive surgical technique that uses percutaneously inserted

2006 Health Technology Assessment (HTA) Database.

775. Conformal and intensity-modulated radiation therapy for prostate cancer

.. Directory Publication. 2006 Authors' objectives Three-dimensional conformal radiation therapy (3D CRT) uses advanced computer technology to tailor the radiotherapy beam to the exact size and shape of a tumor, while minimizing incidental irradiation of surrounding normal tissues. Using 3D CRT in patients with prostate cancer allows delivery of higher doses of radiation to the prostate than would be possible with conventional external beam radiation therapy, with the objective of improving local control (...) and, ultimately, survival. Intensity-modulated radiation therapy (IMRT), the latest conformal radiation therapy development, combines two advanced concepts to deliver 3D CRT to tumors at the higher dosages with enhanced precision: (1) inverse treatment planning with optimization by computer; and (2) computer-controlled intensity modulation of the radiation beam during treatment. Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH Prostatic Neoplasms

2006 Health Technology Assessment (HTA) Database.

776. Satraplatin for second-line hormone-refractory prostate cancer: horizon scanning technology briefing

Satraplatin for second-line hormone-refractory prostate cancer: horizon scanning technology briefing Satraplatin for second-line hormone-refractory prostate cancer: horizon scanning technology briefing Satraplatin for second-line hormone-refractory prostate cancer: horizon scanning technology briefing NHSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA (...) database. Citation NHSC. Satraplatin for second-line hormone-refractory prostate cancer: horizon scanning technology briefing. Birmingham: National Horizon Scanning Centre (NHSC). 2006 Authors' objectives To summarise the currently available evidence on satraplatin for second-line hormone-refractory prostate cancer. Timeliness warning Available on request from NHSC. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Antineoplastic Agents; Organoplatinum Compounds; Prostatic

2006 Health Technology Assessment (HTA) Database.

777. Androgen deprivation treatment (hormonal therapy) for the management of prostate cancer

Androgen deprivation treatment (hormonal therapy) for the management of prostate cancer Androgen deprivation treatment (hormonal therapy) for the management of prostate cancer Androgen deprivation treatment (hormonal therapy) for the management of prostate cancer Augustovski F, Colantonio L, Pichon Riviere A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA (...) database. Citation Augustovski F, Colantonio L, Pichon Riviere A. Androgen deprivation treatment (hormonal therapy) for the management of prostate cancer. Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe Tecnico Breve No.30. 2006 Authors' objectives The aim of this report was to assess current recommendations on androgen deprivation treatment for the management of prostate cancer. Authors' conclusions There is great consensus on recommending hormonal therapy

2006 Health Technology Assessment (HTA) Database.

778. Simultaneous irradiation (ProstRcision) for localized prostate cancer

Simultaneous irradiation (ProstRcision) for localized prostate cancer Simultaneous irradiation (ProstRcision) for localized prostate cancer Simultaneous irradiation (ProstRcision) for localized prostate cancer HAYES, Inc. Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc.. Simultaneous irradiation (ProstRcision) for localized prostate cancer. Lansdale (...) : HAYES, Inc.. Directory Publication. 2006 Authors' objectives Simultaneous irradiation, or ProstRcision, is a prostate cancer treatment provided exclusively at the Radiotherapy Clinics of Georgia. It involves high-dose brachytherapy followed by external beam radiation therapy while the brachytherapy seeds are still active. An integral part of the procedure is the targeting of a post-treatment serum prostate-specific antigen (PSA) nadir of 0.2 ng/mL and an assessment of treatment failure if the PSA

2006 Health Technology Assessment (HTA) Database.

779. Magnetic resonance spectroscopy for prostate cancer: horizon scanning technology briefing

resonance spectroscopy for prostate cancer: horizon scanning technology briefing. Birmingham: National Horizon Scanning Centre (NHSC). 2006 Authors' objectives This study examines the use of magnetic resonance spectroscopy for prostate cancer. Timeliness warning Available on request from NHSC. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Magnetic Resonance Spectroscopy /diagnostic use; Prostatic Neoplasms /diagnosis Language Published English Country of organisation (...) Magnetic resonance spectroscopy for prostate cancer: horizon scanning technology briefing Magnetic resonance spectroscopy for prostate cancer: horizon scanning technology briefing Magnetic resonance spectroscopy for prostate cancer: horizon scanning technology briefing NHSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHSC. Magnetic

2006 Health Technology Assessment (HTA) Database.

780. Prostate cancer gene 3 (Progensa PCA3) assay in the diagnosis of prostate cancer: horizon scanning technology briefing

Prostate cancer gene 3 (Progensa PCA3) assay in the diagnosis of prostate cancer: horizon scanning technology briefing Prostate cancer gene 3 (Progensa PCA3) assay in the diagnosis of prostate cancer: horizon scanning technology briefing Prostate cancer gene 3 (Progensa PCA3) assay in the diagnosis of prostate cancer: horizon scanning technology briefing NHSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation (...) of the quality of this assessment has been made for the HTA database. Citation NHSC. Prostate cancer gene 3 (Progensa PCA3) assay in the diagnosis of prostate cancer: horizon scanning technology briefing. Birmingham: National Horizon Scanning Centre (NHSC). 2006 Authors' objectives This study examines the use of prostate cancer gene 3 (Progensa PCA3) assay in the diagnosis of prostate cancer. Timeliness warning Available on request from NHSC. Final publication URL Indexing Status Subject indexing assigned

2006 Health Technology Assessment (HTA) Database.